Urea Cycle
- Compartment
- Mitochondrial matrix + cytosol
- Main tissue
- Liver (periportal hepatocytes)
- Rate-limiting
- Carbamoyl phosphate synthetase I (CPS I)
- Steps
- 5
Reaction steps
In source order, 5 total
-
1
NH₄⁺ + HCO₃⁻ + 2 ATP → carbamoyl phosphate + 2 ADP + Pᵢ
Carbamoyl phosphate synthetase I (CPS I) 6.3.4.16 ST-0141 Irreversible rate-limiting ATP Pi Bicarbonate/CO2› Notes
In the mitochondrial matrix, carbamoyl phosphate synthetase I (CPS I) uses MgATP and requires N-acetylglutamate (NAG) as an obligatory allosteric activator. This is the rate-limiting, committed, and essentially irreversible step of the urea cycle; it consumes two high-energy phosphate bonds.
-
2
Carbamoyl phosphate + ornithine → citrulline + Pᵢ
› Notes
Ornithine transcarbamylase (OTC) catalyzes this mitochondrial reaction without direct ATP use. Citrulline is exported to the cytosol in exchange for ornithine; the reaction is effectively irreversible under physiological conditions because carbamoyl phosphate is high energy.
-
3
Citrulline + L-aspartate + ATP → argininosuccinate + AMP + PPᵢ
› Notes
Cytosolic argininosuccinate synthetase (ASS1) activates citrulline and adds aspartate. MgATP is cleaved to AMP + PPᵢ, making this an essentially irreversible step that consumes two additional high-energy phosphate equivalents.
-
4
Argininosuccinate → L-arginine + fumarate
› Notes
Cytosolic argininosuccinate lyase (ASL) cleaves argininosuccinate without a required redox cofactor. Fumarate enters the aspartate–argininosuccinate shunt, where it can be converted through malate and oxaloacetate to aspartate, linking the cycle to the tricarboxylic acid cycle.
-
5
L-arginine + H₂O → L-ornithine + urea
› Notes
Cytosolic arginase I (ARG1), a manganese-containing enzyme, hydrolyzes arginine to urea and ornithine. This essentially irreversible final step regenerates ornithine for mitochondrial import and releases urea into blood for renal excretion.
Showing all 5 steps.
Regulation
What speeds each enzyme up and what slows it down
Carbamoyl phosphate synthetase I (CPS I)
N-acetylglutamate (obligatory); increased mitochondrial ammonia
Absence of N-acetylglutamate; no principal direct physiologic inhibitor
Glucagon and cortisol increase expression during fasting/high-protein catabolism; insulin lowers net ureagenic demand in the fed state
N-acetylglutamate synthase (NAGS)
Arginine activates NAGS; acetyl-CoA and glutamate availability
Deficient arginine or acetyl-CoA availability
Induced with sustained high-protein intake and catabolic hormonal states
Arginase I
Arginine availability; manganese
Product accumulation; severe hepatic dysfunction
Long-term expression rises with increased amino-acid catabolism; predominantly indirect hormonal control
Overview
The urea cycle converts toxic ammonia and the amino nitrogen of aspartate into urea, the principal nitrogenous waste product in humans. It is essential during amino-acid catabolism, especially after a protein-rich meal, prolonged fasting, trauma, or uncontrolled diabetes. One nitrogen of urea enters as free mitochondrial ammonia and the other enters as cytosolic aspartate; its carbonyl carbon is derived from bicarbonate.
Cellular location
The cycle is confined to the liver. Steps 1–2 occur in the mitochondrial matrix of hepatocytes, whereas steps 3–5 occur in the cytosol; ornithine and citrulline traverse the inner mitochondrial membrane through the ornithine–citrulline antiporter (ORNT1). Periportal hepatocytes are specialized for high-capacity ureagenesis, while perivenous hepatocytes scavenge residual ammonia through glutamine synthetase.
Net energetics
The net reaction is approximately: NH₄⁺ + HCO₃⁻ + aspartate + 3 ATP + 2 H₂O → urea + fumarate + 2 ADP + AMP + 4 Pᵢ. The cycle consumes 3 ATP molecules but 4 high-energy phosphate bonds per urea (two ATP → two ADP in CPS I and one ATP → AMP in ASS1). Fumarate oxidation through malate to oxaloacetate can generate one cytosolic NADH, partly offsetting the energetic cost when its reducing equivalent is oxidized.
Clinical significance
The urea cycle prevents accumulation of ammonia generated by amino-acid, nucleotide, and amine metabolism. Inherited defects in NAGS, CPS1, OTC, ASS1 (citrullinemia type I), ASL (argininosuccinic aciduria), or ARG1 cause hyperammonemia, often with vomiting, lethargy, cerebral edema, and encephalopathy. OTC deficiency is X-linked and commonly produces elevated urinary orotic acid because excess mitochondrial carbamoyl phosphate enters cytosolic pyrimidine synthesis; this distinguishes it from CPS1 deficiency.
Recent literature
Live Europe PMC search
Europe PMC · fetched just now · sorted by publication date
-
1
Engineering nonconventional yeasts to produce carboxylic acids: Advances and Prospects.
Zhang L, Fan Y, Shi W, Zhou X. · 2026-07-16
open access unreviewed -
2
Investigating seizures in bariatric surgery patients: Pre- and postoperative perspectives: A systematic review.
Bidares M, Aziz M, Samadzadeh S, Bidares R, Pouwels S, Ahmad SJS, Pape-Köhler C. · 2026-09-02
open access unreviewed -
3
Distinct metabolomic signatures of SGLT2 inhibitor vs. sulfonylurea in a paired human liver biopsy study.
Takeshita Y, Oo HK, Nakano Y, Ueno A, Oishi M, Tsujiguchi H, Soga T, Yamashita T, Honda M, Takamura T. · 2026-09-14
open access unreviewed -
4
Diammonium phosphate supplementation in low-protein diets improves nitrogen utilization and feed efficiency without impairing carcass traits or meat quality in finishing pigs.
Zeng X, Tang Y, Li S, Wang Q, Yang H. · 2026-07-02
open access unreviewed -
5
Hyperammonemia: a review of etiologies, whole-exome sequencing diagnosis, and Iranian case reports.
Hajati R, Kamfar S, Seyfi R, Sayad A. · 2026-09-11
unreviewed -
6
Determinants of enteric hyperoxaluria in the SAMP1/YitFc mouse model of spontaneous ileitis.
Zaidan N, Jaber K, Ho M, Zhou B, Pei Z, Bui ML, Cardozo L, Merritts K, Mishra R, Xiong X, Kim Y, Wu M, Knight… · 2026-09-06
open access unreviewed -
7
When safe is not safe together: Co-exposure to individually sub-cytotoxic compounds alters functional integrity of HepG2-derived liver 3D spheroids.
Ghasemzadeh-Hasankolaei M, McCormick S, Magne L, Vrana NE, Ghaemmaghami AM. · 2026-08-29
unreviewed -
8
Revisiting gut microbiota-driven ammonia metabolism: from disease burden to physiological adaptation.
Chen H, Wang Z, Huang J, Yu Z. · 2026-08-25
open access unreviewed -
9
Gut microbiome signatures during acute infection are associated with long COVID.
Comba IY, Mars RAT, Yang L, Dumais M, Chen J, Van Gorp TM, Harrington JJ, Sinnwell JP, Johnson S, Holland LA,… · 2026-08-19
cited 2× open access unreviewed -
10
Pathogenicity and virulence of Crimean-Congo hemorrhagic fever virus: From enzootic maintenance to severe human disease.
Aida-Ficken V, Sorvillo TE, Karaaslan E, Davies KA, Bergeron É, Welch SR, Spengler JR. · 2026-08-05
open access unreviewed
External claims. These come from an index outside this database and are not checked against it. Treat them as leads.